Randall Michael Giuffre, Director at DiaMedica Therapeutics Inc. (DMAC), bought 24,874 shares at $1.40 ($35K) on 2022-12-07, disclosed to the SEC on 2022-12-08.
Open-market purchase of $35k DMAC by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.35 | 2,300 | $3K | 8.9% |
| 2 | $1.40 | 22,574 | $32K | 91.1% |
| Total | $1.40 avg | 24,874 | $35K | 100% |
| Filing → |
| DMAC | BUY | 2022-12-05 | $975 | — | Filing → |
| DMAC | BUY | 2022-12-01 | $136K | — | Filing → |
| DMAC | BUY | 2020-11-23 | $64K | — | Filing → |